EUVIMEDEUVIMED entdecken
Crossref

Optical Genome Mapping in Myelodysplastic Syndromes: Clinical Value and Limitations Derived From a Cohort of 236 Patients

Qing Wei, Sa A Wang, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna, Gokce A Toruner, Shimin Hu, Sanam Loghavi, Chi Young Ok, L Jeffrey Medeiros, Guilin Tang

Modern Pathology · 2025

DOI: 10.1016/j.modpat.2025.100862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Qing Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Chromosome Mapping. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identification of cytogenetic abnormalities is critical for the classification and risk stratification of myelodysplastic syndromes (MDS). Optical genome mapping (OGM) is an emerging cytogenomic platform that enables high-resolution genome-wide cytogenetic analysis. We analyzed bone marrow specimens of 236 MDS patients, 149 newly diagnosed and 87 with relapsed/refractory disease, using OGM, conventional karyotyping, and next-generation sequencing analysis. OGM and karyotyping showed concordant results in 68% of cases, including 34% with normal findings by both assays. OGM provided additional information in 27% of patients. Common abnormalities detected exclusively by OGM included chromoanagenesis (n = 33), KMT2A partial tandem duplication (n = 7), and MECOM rearrangement (n = 4). These OGM findings led to disease reclassification and/or changes in risk stratification in 14 patients (9.4%) with newly diagnosed MDS. In contrast, OGM failed to detect small clones or subclones in 5% of patients, resulting in risk group changes in 2% of newly diagnosed MDS patients. We conclude that OGM enhances the cytogenetic assessment of MDS in approximately 25% of patients and leads to a change in disease classification and/or risk stratification in approximately 10% of patients. However, low sensitivity for detecting small clones or subclones remains a limitation of OGM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesChromosome MappingHumansMaleFemaleAgedMiddle AgedAged, 80 and overAdultKaryotypingHigh-Throughput Nucleotide SequencingYoung AdultChromosome AberrationsCytogenetic Analysis

Stichwörter der Autor:innen

disease classificationkaryotypemyelodysplastic syndromeoptical genome mappingrisk stratification

Autor:innen und Institutionen

  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: gtang@mdanderson.org.

Zitieren

APA

Wei, Q., Wang, S. A., Garcia-Manero, G., Kanagal-Shamanna, R., Toruner, G. A., Hu, S., Loghavi, S., Ok, C. Y., Medeiros, L. J., & Tang, G. (2025). Optical Genome Mapping in Myelodysplastic Syndromes: Clinical Value and Limitations Derived From a Cohort of 236 Patients. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100862

Vancouver

Wei Q, Wang SA, Garcia-Manero G, Kanagal-Shamanna R, Toruner GA, Hu S, et al. Optical Genome Mapping in Myelodysplastic Syndromes: Clinical Value and Limitations Derived From a Cohort of 236 Patients. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100862

BibTeX
@article{Wei2025,
  author = {Wei, Qing and Wang, Sa A and Garcia-Manero, Guillermo and Kanagal-Shamanna, Rashmi and Toruner, Gokce A and Hu, Shimin and Loghavi, Sanam and Ok, Chi Young and Medeiros, L Jeffrey and Tang, Guilin},
  title = {Optical Genome Mapping in Myelodysplastic Syndromes: Clinical Value and Limitations Derived From a Cohort of 236 Patients},
  journal = {Modern Pathology},
  year = {2025},
  doi = {10.1016/j.modpat.2025.100862}
}
Kostenlos starten →